
Prostate Cancer Nuclear Medicine Diagnostics Market by Type (PET, SPECT), Product (C-11, F-18, Ga 68 PSMA) - Global Forecast 2024-2030
Description
Prostate Cancer Nuclear Medicine Diagnostics Market by Type (PET, SPECT), Product (C-11, F-18, Ga 68 PSMA) - Global Forecast 2024-2030
The Prostate Cancer Nuclear Medicine Diagnostics Market size was estimated at USD 1.03 billion in 2023 and expected to reach USD 1.15 billion in 2024, at a CAGR 12.76% to reach USD 2.39 billion by 2030.
Global Prostate Cancer Nuclear Medicine Diagnostics Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Prostate Cancer Nuclear Medicine Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Prostate Cancer Nuclear Medicine Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Prostate Cancer Nuclear Medicine Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Blue Earth Diagnostics, Inc., Bracco Diagnostic Inc., Cardinal Health, Inc, General Electric Company, Global Medical Solutions LLC, Jubilant DraxImage, Inc., Jubilant Pharma Limited, Lantheus Holdings, Inc., NCM-USA LLC, NorthStar Medical Radioisotopes, LLC, Novartis AG, Petnet Solutions Inc. by Siemens Healthcare Private Limited, SHINE Medical Technologies, LLC, and Telix Pharmaceuticals Limited.
Market Segmentation & Coverage
This research report categorizes the Prostate Cancer Nuclear Medicine Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:
Type
PET
SPECT
Product
C-11
F-18
Ga 68 PSMA
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Prostate Cancer Nuclear Medicine Diagnostics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Prostate Cancer Nuclear Medicine Diagnostics Market?
3. What are the technology trends and regulatory frameworks in the Prostate Cancer Nuclear Medicine Diagnostics Market?
4. What is the market share of the leading vendors in the Prostate Cancer Nuclear Medicine Diagnostics Market?
5. Which modes and strategic moves are suitable for entering the Prostate Cancer Nuclear Medicine Diagnostics Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
196 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Prostate Cancer Nuclear Medicine Diagnostics Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing incidences of prostate cancer worldwide necessitates early diagnosis
- 5.1.1.2. Potential development of novel imaging agents to enhance prostate cancer detection
- 5.1.1.3. Increasing adoption of diagnostic procedures such as PET diagnostic tool attributed to higher accuracy
- 5.1.2. Restraints
- 5.1.2.1. Relatively high cost of the testing
- 5.1.3. Opportunities
- 5.1.3.1. Availability of reimbursement policies in developed and developing economies
- 5.1.3.2. Rising research for the development of innovative imaging agents
- 5.1.4. Challenges
- 5.1.4.1. Stringent regulations pertinent to storage and use of radiopharmaceuticals
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Prostate Cancer Nuclear Medicine Diagnostics Market, by Type
- 6.1. Introduction
- 6.2. PET
- 6.3. SPECT
- 7. Prostate Cancer Nuclear Medicine Diagnostics Market, by Product
- 7.1. Introduction
- 7.2. C-11
- 7.3. F-18
- 7.4. Ga 68 PSMA
- 8. Americas Prostate Cancer Nuclear Medicine Diagnostics Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
- 9. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
- 10. Europe, Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
- 11. Competitive Landscape
- 11.1. FPNV Positioning Matrix
- 11.2. Market Share Analysis, By Key Player
- 11.3. Competitive Scenario Analysis, By Key Player
- 12. Competitive Portfolio
- 12.1. Key Company Profiles
- 12.1.1. Bayer AG
- 12.1.2. Blue Earth Diagnostics, Inc.
- 12.1.3. Bracco Diagnostic Inc.
- 12.1.4. Cardinal Health, Inc
- 12.1.5. General Electric Company
- 12.1.6. Global Medical Solutions LLC
- 12.1.7. Jubilant DraxImage, Inc.
- 12.1.8. Jubilant Pharma Limited
- 12.1.9. Lantheus Holdings, Inc.
- 12.1.10. NCM-USA LLC
- 12.1.11. NorthStar Medical Radioisotopes, LLC
- 12.1.12. Novartis AG
- 12.1.13. Petnet Solutions Inc. by Siemens Healthcare Private Limited
- 12.1.14. SHINE Medical Technologies, LLC
- 12.1.15. Telix Pharmaceuticals Limited
- 12.2. Key Product Portfolio
- 13. Appendix
- 13.1. Discussion Guide
- 13.2. License & Pricing
- FIGURE 1. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET RESEARCH PROCESS
- FIGURE 2. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2023 VS 2030
- FIGURE 3. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET DYNAMICS
- FIGURE 7. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
- FIGURE 8. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
- FIGURE 10. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 12. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 14. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 20. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.